The median age, ALBI score, and ALBI grade were significantly higher in the AT group than in the non-AT group; however, there were no significant differences in sex, cause of HCC, tumor size, tumor number, TACE condition before treatment with LEN, or AFP and DCP levels in the two groups (Table 1). The gene discussed is ACE; the disease is hepatocellular carcinoma.